CARDIFF ONCOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2013-12-31 was 0.00 shares.
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2013 was 41.67K shares, a 20733.50% increase from fiscal 2012.
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2012 was 200.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2013-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | 41.67K shares 10-K · filed 2014-03-17 |
| 2012-12-31 | 200.00 shares 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |